{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:00:32Z","timestamp":1787014832894,"version":"build-2736575974"},"reference-count":62,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2004,2,1]],"date-time":"2004-02-01T00:00:00Z","timestamp":1075593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,7]],"date-time":"2015-12-07T00:00:00Z","timestamp":1449446400000},"content-version":"vor","delay-in-days":4327,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2004,2]]},"DOI":"10.1111\/j.1523-1755.2004.00440.x","type":"journal-article","created":{"date-parts":[[2004,1,8]],"date-time":"2004-01-08T10:42:33Z","timestamp":1073558553000},"page":"744-753","source":"Crossref","is-referenced-by-count":16,"title":["Fabry disease: Kidney involvement and enzyme replacement therapy"],"prefix":"10.1016","volume":"65","author":[{"given":"Kostas C.","family":"Siamopoulos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/j.1523-1755.2004.00440.x_bb0010","first-page":"3733","article-title":"\u03b1-Galactosidase A deficiency: Fabry disease,","volume":"vol 3","author":"Desnick","year":"2001"},{"key":"10.1111\/j.1523-1755.2004.00440.x_bb0015","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jama.281.3.249","article-title":"Prevalence of lysosomal storage disorders","volume":"281","author":"Meikle","year":"1999","journal-title":"JAMA"},{"key":"10.1111\/j.1523-1755.2004.00440.x_bb0020","doi-asserted-by":"crossref","first-page":"4859","DOI":"10.1073\/pnas.83.13.4859","article-title":"Human \u03b1-galactosidase A: Nucleotide sequence of a cDNA clone encoding the mature enzyme","volume":"83","author":"Bishop","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1111\/j.1523-1755.2004.00440.x_bb0025","series-title":"Lipid Storage Disorders","first-page":"809","article-title":"Human \u03b1-galactosidase: Characterization and eukaryotic expression of the full-length cDNA and structural organization of the gene,","author":"Bishop","year":"1988"},{"key":"10.1111\/j.1523-1755.2004.00440.x_bb0030","doi-asserted-by":"crossref","first-page":"3301","DOI":"10.1093\/nar\/17.8.3301","article-title":"Nucleotide sequence of the human alpha-galactosidase A gene","volume":"17","author":"Kornreich","year":"1989","journal-title":"Nucleic Acids Res"},{"key":"10.1111\/j.1523-1755.2004.00440.x_bb0035","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1006\/geno.1999.5820","article-title":"Integrated STS\/YAC physical, genetic, and transcript map of human Xq21.3 to q23\/q24 (DXS1203-DXS1059)","volume":"58","author":"Srivastava","year":"1999","journal-title":"Genomics"},{"key":"10.1111\/j.1523-1755.2004.00440.x_bb0040","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S1096-7192(02)00151-8","article-title":"Structural basis of Fabry disease","volume":"77","author":"Garman","year":"2002","journal-title":"Mol Genet Metab"},{"key":"10.1111\/j.1523-1755.2004.00440.x_bb0045","first-page":"67","article-title":"Angiokeratoma corporis diffusum: Fabry's disease","volume":"34","author":"Colombi","year":"1967","journal-title":"Helv Med Acta"},{"key":"10.1111\/j.1523-1755.2004.00440.x_bb0050","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1056\/NEJM199102073240607","article-title":"An atypical variant of Fabry's disease with manifestations confined to the myocardium","volume":"324","author":"Von Scheidt","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1523-1755.2004.00440.x_bb0055","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1056\/NEJM199508033330504","article-title":"An atypical variant of Fabry's disease in men with left ventricular hypertrophy","volume":"333","author":"Nakao","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1523-1755.2004.00440.x_bb0060","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1161\/01.CIR.0000012626.81324.38","article-title":"Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy","volume":"105","author":"Sachdev","year":"2002","journal-title":"Circulation"},{"issue":"Suppl 7","key":"10.1111\/j.1523-1755.2004.00440.x_bb0065","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/ndt\/11.supp7.4","article-title":"Rare diseases in renal replacement therapy in the ERA-EDTA Registry","volume":"11","author":"Tsakiris","year":"1996","journal-title":"Nephrol Dial Transplant"},{"key":"10.1111\/j.1523-1755.2004.00440.x_bb0070","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1046\/j.1523-1755.2002.00097.x","article-title":"Patients with Fabry disease on dialysis in the United States","volume":"61","author":"Thadhani","year":"2002","journal-title":"Kidney Int"},{"key":"10.1111\/j.1523-1755.2004.00440.x_bb0075","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/jmg.38.11.769","article-title":"Anderson-Fabry disease: Clinical manifestations and impact of disease in a cohort of 60 obligate carrier females","volume":"38","author":"MacDermot","year":"2001","journal-title":"J Med Genet"},{"key":"10.1111\/j.1523-1755.2004.00440.x_bb0080","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1023\/A:1012993305223","article-title":"Anderson-Fabry disease: Clinical manifestations of disease in female heterozygotes","volume":"24","author":"Whybra","year":"2001","journal-title":"J Inherit Metab Dis"},{"key":"10.1111\/j.1523-1755.2004.00440.x_bb0085","first-page":"227","article-title":"Fabry disease: 22 novel mutations in the alpha-galactosidase A gene and genotype\/phenotype correlations in severely and mildly affected hemizygotes and heterozygotes","volume":"48","author":"Ashton-Prolla","year":"2000","journal-title":"J Investig Med"},{"key":"10.1111\/j.1523-1755.2004.00440.x_bb0090","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/00005792-200203000-00003","article-title":"Natural history of Fabry renal disease: Influence of alpha-galactosidase A activity and genetic mutations on clinical course","volume":"81","author":"Branton","year":"2002","journal-title":"Medicine (Baltimore)"},{"issue":"Suppl 2","key":"10.1111\/j.1523-1755.2004.00440.x_bb0095","doi-asserted-by":"crossref","first-page":"S130","DOI":"10.1097\/01.ASN.0000015236.70757.C4","article-title":"Biochemical and molecular genetic basis of Fabry disease","volume":"13","author":"Pastores","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1111\/j.1523-1755.2004.00440.x_bb0100","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/bmj.285.6343.685","article-title":"Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy","volume":"285","author":"Mogensen","year":"1982","journal-title":"BMJ"},{"key":"10.1111\/j.1523-1755.2004.00440.x_bb0105","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1007\/BF02374501","article-title":"The course of kidney function in type 2 (non\u2013insulin-dependent) diabetic patients with diabetic nephropathy","volume":"36","author":"Gall","year":"1993","journal-title":"Diabetologia"},{"key":"10.1111\/j.1523-1755.2004.00440.x_bb0110","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0272-6386(96)90538-7","article-title":"Diabetic nephropathy in type II diabetes","volume":"27","author":"Ritz","year":"1996","journal-title":"Am J Kidney Dis"},{"key":"10.1111\/j.1523-1755.2004.00440.x_bb0115","doi-asserted-by":"crossref","first-page":"715","DOI":"10.2337\/diab.42.5.715","article-title":"Impact of arterial blood pressure and albuminuria on the progression of diabetic nephropathy in IDDM patients","volume":"42","author":"Rossing","year":"1993","journal-title":"Diabetes"},{"key":"10.1111\/j.1523-1755.2004.00440.x_bb0120","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1038\/ki.1996.481","article-title":"Predictors of the progression of renal insufficiency in patients with insulin-dependent diabetes and overt diabetic nephropathy. The Collaborative Study Group","volume":"50","author":"Breyer","year":"1996","journal-title":"Kidney Int"},{"key":"10.1111\/j.1523-1755.2004.00440.x_bb0125","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s001250050694","article-title":"Predictors of the progression of diabetic nephropathy and the beneficial effect of angiotensin-converting enzyme inhibitors in NIDDM patients","volume":"40","author":"Yokoyama","year":"1997","journal-title":"Diabetologia"},{"key":"10.1111\/j.1523-1755.2004.00440.x_bb0130","doi-asserted-by":"crossref","first-page":"754","DOI":"10.7326\/0003-4819-123-10-199511150-00003","article-title":"Blood pressure control, proteinuria, and the progression of renal disease: The Modification of Diet in Renal Disease Study","volume":"123","author":"Peterson","year":"1995","journal-title":"Ann Intern Med"},{"key":"10.1111\/j.1523-1755.2004.00440.x_bb0135","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/j.1399-0004.1987.tb02820.x","article-title":"Effect of vitamin E and ticlopidine on platelet aggregation in Fabry's disease","volume":"31","author":"Sakuraba","year":"1987","journal-title":"Clin Genet"},{"key":"10.1111\/j.1523-1755.2004.00440.x_bb0140","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/1531-8249(200002)47:2<229::AID-ANA13>3.0.CO;2-T","article-title":"Profile of endothelial and leukocyte activation in Fabry patients","volume":"47","author":"DeGraba","year":"2000","journal-title":"Ann Neurol"},{"key":"10.1111\/j.1523-1755.2004.00440.x_bb0145","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/S0140-6736(96)11445-8","article-title":"Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy","volume":"349","author":"The GISEN Group","year":"1997","journal-title":"Lancet"},{"key":"10.1111\/j.1523-1755.2004.00440.x_bb0150","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/S0140-6736(83)92462-5","article-title":"Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy","volume":"1","author":"Parving","year":"1983","journal-title":"Lancet"},{"key":"10.1111\/j.1523-1755.2004.00440.x_bb0155","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1136\/bmj.297.6656.1086","article-title":"Protection of kidney function and decrease in albuminuria by captopril in insulin dependent diabetics with nephropathy","volume":"297","author":"Parving","year":"1988","journal-title":"BMJ"},{"key":"10.1111\/j.1523-1755.2004.00440.x_bb0160","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1523-1755.2004.00440.x_bb0165","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/bmj.304.6823.339","article-title":"Renal protective effect of enalapril in diabetic nephropathy","volume":"304","author":"Bjorck","year":"1992","journal-title":"BMJ"},{"key":"10.1111\/j.1523-1755.2004.00440.x_bb0170","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1053\/ajkd.2001.22069","article-title":"Late escape from the antiproteinuric effect of ACE inhibitors in nondiabetic renal disease","volume":"37","author":"Shiigai","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1111\/j.1523-1755.2004.00440.x_bb0175","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1046\/j.1523-1755.2002.00675.x","article-title":"Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy","volume":"62","author":"Thurberg","year":"2002","journal-title":"Kidney Int"},{"key":"10.1111\/j.1523-1755.2004.00440.x_bb0180","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1056\/NEJM197104082841401","article-title":"Diagnosis of glycosphingolipidoses by urinary-sediment analysis","volume":"284","author":"Desnick","year":"1971","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1523-1755.2004.00440.x_bb0185","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/ki.1978.32","article-title":"Early renal changes in hemizygous and heterozygous patients with Fabry's disease","volume":"13","author":"Gubler","year":"1978","journal-title":"Kidney Int"},{"issue":"Suppl 2","key":"10.1111\/j.1523-1755.2004.00440.x_bb0190","doi-asserted-by":"crossref","first-page":"S134","DOI":"10.1097\/01.ASN.0000016684.07368.75","article-title":"Renal pathology in Fabry disease","volume":"13","author":"Alroy","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1111\/j.1523-1755.2004.00440.x_bb0195","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/0002-9343(73)90140-X","article-title":"Renal pathologic lesions and functional alterations in a man with Fabry's disease","volume":"55","author":"Pabico","year":"1973","journal-title":"Am J Med"},{"key":"10.1111\/j.1523-1755.2004.00440.x_bb0200","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: A randomized controlled trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA"},{"key":"10.1111\/j.1523-1755.2004.00440.x_bb0205","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human \u03b1-galactosidase A replacement therapy in Fabry's disease","volume":"345","author":"Eng","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1523-1755.2004.00440.x_bb0210","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/0003-9861(83)90203-5","article-title":"Biosynthesis of \u03b1-galactosidase A in cultured Chang liver cells","volume":"224","author":"DeDunne","year":"1983","journal-title":"Arch Biochem Biophys"},{"key":"10.1111\/j.1523-1755.2004.00440.x_bb0215","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1016\/S0021-9258(18)61618-7","article-title":"Synthesis and processing of alpha-galactosidase A in human fibroblasts. Evidence for different mutation in Fabry disease","volume":"262","author":"Lemansky","year":"1987","journal-title":"J Biol Chem"},{"key":"10.1111\/j.1523-1755.2004.00440.x_bb0220","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1006\/abio.1998.2966","article-title":"Quantitative determination of globotriaosylceramide by immunodetection of glycolipid-bound recombinant verotoxin B subunit","volume":"267","author":"Zeidner","year":"1999","journal-title":"Anal Biochem"},{"key":"10.1111\/j.1523-1755.2004.00440.x_bb0225","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1086\/318809","article-title":"A phase I\/II clinical trial of enzyme replacement in Fabry disease: Pharmacokinetic, substrate clearance, and safety studies","volume":"68","author":"Eng","year":"2001","journal-title":"Am J Hum Genet"},{"key":"10.1111\/j.1523-1755.2004.00440.x_bb0230","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/ki.1983.203","article-title":"Cell renewal of glomerular cell types in normal rat. An autoradiographic analysis","volume":"24","author":"Pabst","year":"1983","journal-title":"Kidney Int"},{"key":"10.1111\/j.1523-1755.2004.00440.x_bb0235","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1681\/ASN.V4122032","article-title":"Proliferative activity of intrinsic cell populations in the normal human kidney","volume":"4","author":"Nadasdy","year":"1994","journal-title":"J Am Soc Nephrol"},{"key":"10.1111\/j.1523-1755.2004.00440.x_bb0240","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/S0002-9440(10)65739-2","article-title":"Cell cyclic regulation and differentiation in the human podocyte lineage","volume":"153","author":"Nagata","year":"1998","journal-title":"Am J Pathol"},{"key":"10.1111\/j.1523-1755.2004.00440.x_bb0245","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/ki.1978.32","article-title":"Early renal changes in hemizygous and heterozygous patients with Fabry's disease","volume":"13","author":"Gubler","year":"1978","journal-title":"Kidney Int"},{"key":"10.1111\/j.1523-1755.2004.00440.x_bb0250","first-page":"85","article-title":"Diagnostic value of kidney biopsy in heterozygous Fabry's disease","volume":"109","author":"Farge","year":"1985","journal-title":"Arch Pathol Lab Med"},{"key":"10.1111\/j.1523-1755.2004.00440.x_bb0255","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1159\/000247189","article-title":"Fabry's disease: Heterozygous form of different expression in two monozygous twin sisters","volume":"187","author":"Marguery","year":"1993","journal-title":"Dermatology"},{"key":"10.1111\/j.1523-1755.2004.00440.x_bb0260","first-page":"89","article-title":"Fabry's disease in a heterozygous woman","volume":"109","author":"Rodriguez","year":"1985","journal-title":"Arch Pathol Lab Med"},{"key":"10.1111\/j.1523-1755.2004.00440.x_bb0265","doi-asserted-by":"crossref","first-page":"338","DOI":"10.7326\/0003-4819-138-4-200302180-00014","article-title":"Fabry disease, an under-recognized multisystem disorder: Expert recommendation for diagnosis, management, and enzyme replacement therapy","volume":"138","author":"Desnick","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1111\/j.1523-1755.2004.00440.x_bb0270","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1517\/13543784.11.10.1467","article-title":"Fabry disease: Recent advances in enzyme replacement therapy","volume":"11","author":"Germain","year":"2002","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1111\/j.1523-1755.2004.00440.x_bb0275","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1046\/j.1523-1755.2000.00864.x","article-title":"Glycosphingolipid depletion in Fabry disease lymphoblasts with potent inhibitors of glycosylceramide synthase","volume":"16","author":"Abe","year":"2000","journal-title":"Kidney Int"},{"key":"10.1111\/j.1523-1755.2004.00440.x_bb0280","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/ajmg.1320070308","article-title":"Plasma exchange removes glycosphingolipid in Fabry disease","volume":"7","author":"Pyfritz","year":"1980","journal-title":"Am J Med Genet"},{"key":"10.1111\/j.1523-1755.2004.00440.x_bb0285","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1089\/10430349950017671","article-title":"Correction of enzymatic and lysosomal storage defects in Fabry mice by adenovirus-mediated gene transfer","volume":"10","author":"Ziegler","year":"1999","journal-title":"Hum Gene Ther"},{"key":"10.1111\/j.1523-1755.2004.00440.x_bb0290","first-page":"1499","article-title":"Fabry's disease: Two patients improved by fetal liver cells","volume":"8","author":"Touraine","year":"1979","journal-title":"Nouv Press Med"},{"key":"10.1111\/j.1523-1755.2004.00440.x_bb0295","first-page":"A503","article-title":"Fabry's disease: Bone marrow transplantation in \u03b1-galactosidase A deficient mice reverses substrate accumulation, except in the kidney","volume":"65","author":"Simonaro","year":"1999","journal-title":"Am J Hum Genet"},{"key":"10.1111\/j.1523-1755.2004.00440.x_bb0305","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1097\/00007890-200006150-00020","article-title":"Excellent outcome of renal transplantation in patients with Fabry's disease","volume":"69","author":"Ojo","year":"2000","journal-title":"Transplantation"},{"key":"10.1111\/j.1523-1755.2004.00440.x_bb0310","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1159\/000060191","article-title":"Long-term survival of patients with renal transplantation in Fabry's disease","volume":"136","author":"Mignani","year":"2001","journal-title":"Contrib Nephrol"},{"key":"10.1111\/j.1523-1755.2004.00440.x_bb0315","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1097\/00007890-199104000-00004","article-title":"Recurrence of Fabry's disease in a renal allograft eleven years after successful renal transplantation","volume":"51","author":"Mosnier","year":"1991","journal-title":"Transplantation"},{"key":"10.1111\/j.1523-1755.2004.00440.x_bb0300","doi-asserted-by":"crossref","first-page":"6423","DOI":"10.1073\/pnas.96.11.6423","article-title":"Aging accentuates and bone marrow transplantation ameliorates metabolic defects in Fabry disease mice","volume":"96","author":"Ohshima","year":"1999","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253815497674?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253815497674?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T16:08:23Z","timestamp":1648742903000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253815497674"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,2]]},"references-count":62,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2004,2]]}},"alternative-id":["S0085253815497674"],"URL":"https:\/\/doi.org\/10.1111\/j.1523-1755.2004.00440.x","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2004,2]]}}}